Results 211 to 220 of about 99,547,245 (298)
Correlation between NRS-2002 scores and PD-1/CTLA-4 expression levels in patients with community-acquired pneumonia. [PDF]
Zhang C +7 more
europepmc +1 more source
ABSTRACT Cadherin 1 (CDH1) encodes E‐cadherin, a key epithelial adhesion molecule traditionally associated with tumor suppression and epithelial–mesenchymal transition (EMT). However, its roles across cancers remain incompletely understood, particularly within multilayer regulatory contexts involving genomic, epigenetic, transcriptional, and immune ...
Md. Abdur Rahman +2 more
wiley +1 more source
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet +36 more
wiley +1 more source
Life-threatening anaphylactic shock induced by cadonilimab (AK104), a PD-1/CTLA-4 bispecific antibody: a case report. [PDF]
Zheng Z, Li J, Huang Q.
europepmc +1 more source
Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC. [PDF]
Gumuzio J +10 more
europepmc +1 more source
ABSTRACT Background For prostate cancer (PCa), early diagnosis and biomarker‐based patient stratification can improve clinical decision‐making and post‐treatment prognosis. PCa biomarkers are best validated in tissue following comprehensive histopathologic review; however, urinary biomarkers can be obtained non‐invasively and are therefore safer and ...
Yuandong Xing +11 more
wiley +1 more source
First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies. [PDF]
Ekström-Rydén V +7 more
europepmc +1 more source
Assessment of Clinical and Immunological Factors of Local Recurrence in Canine Soft Tissue Sarcoma
ABSTRACT Canine soft tissue sarcomas (STSs) are locally invasive tumours, making local recurrence a major clinical challenge. Time to recurrence (TTR) and associated immune factors remain poorly characterized. This study aimed to characterize the immune microenvironment of canine STS and identify factors associated with TTR.
Kazuki Mizuta +2 more
wiley +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source

